Oncogenic activation of the phosphatidylinositol-3-kinase (PI3K), protein kinase B
(PKB/AKT), and mammalian target of rapamycin (mTOR) pathway is a frequent event in …

Activation of the androgen receptor (AR) and AR-driven transcriptional programs is central to
the pathophysiology of prostate cancer. Despite successful translational efforts in targeting …

Huggins and Hodges demonstrated the therapeutic effect of gonadal testosterone
deprivation in the 1940s and therefore firmly established the concept that prostate cancer is …

All aspects of prostate cancer evolution are closely related to androgen levels and the status
of the androgen receptor (AR). Almost all treatments target androgen metabolism pathways …

Castration resistant prostate cancer (CRPC) remains androgen dependant despite castrate
levels of circulating testosterone following androgen deprivation therapy, the first line of …

After androgen deprivation, prostate cancer frequently becomes castration resistant (CRPC),
with intratumoral androgen production from extragonadal precursors that activate the …

Sex-steroid hormones have been investigated for decades for their oncogenic properties in
hormone-dependent cancers. The increasing body of knowledge on the biological actions of …

Androgens play an essential role in prostate cancer. Clinical treatments that target
steroidogenesis and the androgen receptor (AR) successfully postpone disease …

Prostate cancer resistance to next-generation hormonal treatment with enzalutamide is a
major problem and eventuates into disease lethality. Biologically active glucocorticoids that …

Prostate cancer is well known to be dependent on the androgen receptor (AR) for growth
and survival. Thus, AR is the main pharmacological target to treat this disease. However …